Approaches to the identification of non-essential genes of African swine fever virus

Mettraux, Christianne; Ackermann, Mathias; Tratschin, Jon-Duri; Kihm, U

doi:10.1016/0378-1135(92)90039-v

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An effective safe ASFV vaccine is clearly required and there are indications that this is possible [74]. The protective effect of ASFV vaccine is attributed to structural virus proteins, which are produced as long as the vaccine virus was propagated in animals and/or pig macrophage cultures; genes of these protective antigens were lost while the virus was adapted to grow in conventional tissue culture.…”

Section: African Swine Fevermentioning

confidence: 99%

“…The protective effect of ASFV vaccine is attributed to structural virus proteins, which are produced as long as the vaccine virus was propagated in animals and/or pig macrophage cultures; genes of these protective antigens were lost while the virus was adapted to grow in conventional tissue culture. It was concluded that the protective proteins were not essential for virus replication [74,75]. Tissue culture is essential for vaccine production for both conventional and bio-tech virusbased vaccines [2].…”

Section: African Swine Fevermentioning

confidence: 99%

See 1 more Smart Citation

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Patel¹,

Heldens²

2009

Vaccine

View full text Add to dashboard Cite

Since the refinement of tissue culture techniques for virus isolation and propagation from the mid 1960s onwards, veterinary virology has received much academic and industrial interest, and has now become a major global industry largely centred on vaccine development against economically important virus diseases of food animals. Bio-tech approaches have been widely used for improved vaccines development. While many viral diseases are controlled through vaccination, many still lack safe and efficacious vaccines. Additional challenges faced by academia, industry and governments are likely to come from viruses jumping species and also from the emergence of virulent variants of established viruses due to natural mutations. Also viral ecology is changing as the respective vectors adapt to new habitats as has been shown in the recent incursion by bluetongue virus into Europe. In this paper the current vaccines for livestock, horses and birds are described in a species by species order. The new promising bio-tech approaches using reverse genetics, non-replicating viral vectors, alpha virus vectors and genetic vaccines in conjunction with better adjuvants and better ways of vaccine delivery are discussed as well

show abstract

Section: African Swine Fevermentioning

confidence: 99%

Section: African Swine Fevermentioning

confidence: 99%

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Patel¹,

Heldens²

2009

Vaccine

View full text Add to dashboard Cite

show abstract

“…African swine fever (ASF) is a highly contagious fatal disease of pigs caused by an iridovirus (ASFV). An effective vaccine is clearly needed and there are indications that this is possible (Mettraux et al, 1992). Commercial development of the approach has however never been undertaken for economic reasons or has been unsuccessful for reasons such as manufacturing difficulties.…”

Section: Iridoviruses and Orbivirusesmentioning

confidence: 99%

Veterinary vaccine development from an industrial perspective

Heldens¹,

Patel²,

Chanter³

et al. 2008

The Veterinary Journal

View full text Add to dashboard Cite

Veterinary vaccines currently available in Europe and in other parts of the world are developed by the veterinary pharmaceutical industry. The development of a vaccine for veterinary use is an economic endeavour that takes many years. There are many obstacles along the path to the successful development and launch of a vaccine. The industrial development of a vaccine for veterinary use usually starts after the proof of concept that is based on robust academic research. A vaccine can only be made available to the veterinary community once marketing authorisation has been granted by the veterinary authorities. This review gives a brief description of the regulatory requirements which have to be fulfilled before a vaccine can be admitted to the market. Vaccines have to be produced in a quality controlled environment to guarantee delivery of a product of consistent quality with well defined animal and consumer safety and efficacy characteristics. The regulatory and manufacturing legislative framework in which the development takes place is described, as well as the trend in developments in production systems. Recent developments in bacterial, viral and parasite vaccine research and development are also addressed and the development of novel adjuvants that use the expanding knowledge of immunology and disease pathology are described.

show abstract

Isolation and characterization of TK-deficient mutants of African swine fever virus

et al. 1995

View full text Add to dashboard Cite

Approaches to the identification of non-essential genes of African swine fever virus

Cited by 3 publications

References 25 publications

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Immunoprophylaxis against important virus diseases of horses, farm animals and birds

Veterinary vaccine development from an industrial perspective

Isolation and characterization of TK-deficient mutants of African swine fever virus

Contact Info

Product

Resources

About